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Transcriptomic analysis in a Drosophila model identifies 
previously implicated and novel pathways in the therapeutic 
mechanism in neuropsychiatric disorders
Priyanka Singh†, Farhan Mohammad† and Abhay Sharma*
Institute of Genomics and Integrative Biology, Council of Scientific and Industrial Research, Delhi University Campus, Delhi, India
We have taken advantage of a newly described Drosophila model to gain insights into the potential 
mechanism of antiepileptic drugs (AEDs), a group of drugs that are widely used in the treatment 
of several neurological and psychiatric conditions besides epilepsy. In the recently described 
Drosophila model that is inspired by pentylenetetrazole (PTZ) induced kindling epileptogenesis in 
rodents, chronic PTZ treatment for 7 days causes a decreased climbing speed and an altered CNS 
transcriptome, with the latter mimicking gene expression alterations reported in epileptogenesis. 
In the model, an increased climbing speed is further observed 7 days after withdrawal from chronic 
PTZ. We used this post-PTZ withdrawal regime to identify potential AED mechanism. In this regime, 
treatment with each of the five AEDs tested, namely, ethosuximide, gabapentin, vigabatrin, sodium 
valproate, and levetiracetam, resulted in rescuing of the altered climbing behavior. The AEDs 
also normalized PTZ withdrawal induced transcriptomic perturbation in fly heads; whereas AED 
untreated flies showed a large number of up- and down-regulated genes which were enriched in 
several processes including gene expression and cell communication, the AED treated flies showed 
differential expression of only a small number of genes that did not enrich gene expression and cell 
communication processes. Gene expression and cell communication related upregulated genes 
in AED untreated flies overrepresented several pathways – spliceosome, RNA degradation, and 
ribosome in the former category, and inositol phosphate metabolism, phosphatidylinositol signaling, 
endocytosis, and hedgehog signaling in the latter. Transcriptome remodeling effect of AEDs was 
overall confirmed by microarray clustering that clearly separated the profiles of AED treated 
and untreated flies. Besides being consistent with previously implicated pathways, our results 
provide evidence for a role of other pathways in psychiatric drug mechanism. Overall, we provide 
an amenable model to understand neuropsychiatric mechanism in cellular and molecular terms.
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and MAP kinase pathways, and that genes in these pathways show 
increased expression in the brains of rodents exposed to antide-
pressant treatments (Altar et al., 2009).
As with other psychiatric drugs, the long term mechanism of 
antiepileptic drugs (AEDs), which are also used in the treatment of 
various psychiatric conditions besides epilepsy, is poorly understood 
(Rogawski and Loscher, 2004; Johannessen, 2008; Kuzniecky et al., 
2008; Nagarkatti et al., 2008; Nalivaeva et al., 2009). Conceptually, 
transcriptomic analysis in established mammalian models of epilepsy 
and AED testing can be used to gain insights into the mechanisms 
of action of these drugs. However, inherent complexity of mamma-
lian brain does not render these established models as amenable to 
systems modeling (Gorter et al., 2006). Under these circumstances, 
the genetically tractable model organism Drosophila, because of its 
amenability to a wide variety of experimental approaches, including 
functional genomics (Chintapalli et al., 2007), may offer an attrac-
tive system to unravel AED mechanism.
An established model of epileptogenesis and AED testing, kin-
dling in rodents involves long term brain plasticity in which recur-
rent activation of neural pathways through chemical or electrical 
means results in an increased susceptibility to evoked seizures that 
IntroductIon
Drugs used in the treatment of psychiatric disorders are mostly 
known to target neurotransmitter receptors. This receptor mecha-
nism alone however does not provide simple mechanistic inter-
pretations for their long term clinical efficacy (Molteni et al., 
2009; Zhou et al., 2009). In addition to receptor mediated acute 
biochemical effects that may explain short-term clinical response, 
these drugs are considered to exert other long term therapeutic 
effects that may not be directly related to receptor mechanisms 
(Molteni et al., 2009). These long term neuroprotective mecha-
nisms  underlying  psychiatric  drug  action  are  however  poorly 
understood  (McLoughlin  et  al.,  2009).  It  has  been  suggested 
that drug induced changes in gene and protein expression may 
ultimately translate into the overall neuroprotection. Given this, 
genome level expression analysis is considered to offer a prom-
ising approach to identify genes and pathways underlying neu-
ropsychiatric conditions and mechanisms of drug action (Altar 
et al., 2009). For example, a meta-analysis has recently revealed 
that gene expression profiles of brains from persons with major 
depressive disorder show decreased expression of genes related 
to glutamate transport and metabolism, neurotrophic signaling 
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Drosophila model offered a simpler system for identifying poten-
tial mechanism of AEDs at transcriptomic level because it is not 
complicated by continued presence of the GABAA antagonist. We 
thus used the post-PTZ regime in the present analysis. Specifically, 
we tested the concept that if treatment with AEDs after PTZ with-
drawal is found to rescue flies from developing increased climbing 
speed then analyzing CNS expression profiles of flies treated and 
untreated with AEDs may enable identification of transcriptomic 
correlates of AED action.
MaterIals and Methods
BehavIoral pharMacology
The wild type Oregon-R strain of Drosophila melanogaster was used 
in the analysis. Cultures were routinely maintained at 24 ± 1°C, 60% 
RH, and 12 h light (9 AM to 9 PM) and 12 h dark cycle, in normal 
food (NF) consisting of agar–agar, maize powder, brown sugar, 
dried yeast, and nipagin. Standard fly handling and manipulation 
methods were followed. Stringency required in behavioral studies 
was strictly adhered to at several levels including housing condi-
tions, exposure to anesthetic agent, light intensity, etc. Three- to 
4-day-old unmated male flies were used to begin treatment at 0 day 
time-point (Figure 1A). Final concentration of PTZ, ethosuximide 
(ETH), gabapentin (GBP), vigabatrin (VGB), sodium valproate 
(NaVP; all from Sigma-Aldrich), and levetiracetam (LEV; Levesam 
500, Nicholas Piramal) in the fly medium was 8, 3.48, 16, 24, 0.33, 
and 5 mg/ml, in that order. Climbing speed was measured using a 
semi-manual method (Mohammad et al., 2009). In this method, 
individual flies were first familiarized in a vertically placed glass 
column for 90 s and then startle-induced climbing activity was 
recorded using a “dot/comma” method. In “dot/comma” record-
ing, the locomotor activity of a fly was recorded by keep pressing 
the dot key or the comma key of a personal computer, to record 
a climbing or a resting fly, in that order. Using the cursor speed, 
ultimately progresses to spontaneous seizures (Goddard et al., 1969; 
Walker et al., 2002; Husum et al., 2004; Garriga-Canut et al., 2006; 
McNamara et al., 2006; De Smedt et al., 2007). Like epileptogen-
esis, kindling is known to be associated with several non-epileptic 
conditions such as schizophrenia-like behaviors, hyperlocomo-
tor activity, anxiogenic response, hyperalgesia, amnesia, spatial 
learning and memory, and neurodegeneration (Mortazavi et al., 
2005; Pavlova et al., 2006; Szyndler et al., 2006; Akula et al., 2007; 
Howland et al., 2007; Omrani et al., 2007; Ma and Leung, 2010). 
Notably, inspired by pentylenetetrazole (PTZ) kindling in rodents, 
we recently described a Drosophila model of chronic PTZ induced 
alteration in locomotor activity (Mohammad et al., 2009), a behav-
ior that is considered relevant in understanding neuropsychiatric 
conditions (Yamamoto et al., 2008; Iliadi, 2009). In this fly model, 
7 days of PTZ treatment and 7 days of subsequent PTZ discontinu-
ation progressively result in a decreased and an increased speed of 
startle-induced climbing in Drosophila adult, in that order. The 
chronic PTZ regime is responsive to AEDs; flies treated with PTZ 
and AED combined do not exhibit altered locomotor behavior. 
Importantly, downregulation of genes enriched in several proc-
esses such as transcription, cell differentiation, cell communica-
tion, neurogenesis, axonogenesis, axon guidance, and glutamate 
metabolism, etc., characterize the fly head transcriptome in the 
chronic PTZ regime. Moreover, gene expression alteration in the fly 
model has been found to mimic that reported in established mam-
malian models of epileptogenesis and human epileptic patients 
(Mohammad et al., 2009). These findings have suggested that the 
fly model may potentially be used in understanding mechanisms 
of action of AEDs at transcriptomic level.
Here, we describe use of the fly model to gain insights into the 
possible mechanism of AED action. Unlike chronic PTZ regime 
characterized earlier at transcriptomic level (Mohammad et al., 
2009),  the  uncharacterized  post-PTZ  withdrawal  part  of  the 
Figure 1 | Study design for behavioral and transcriptomic analyses. Twelve 
different treatment conditions for behavioral analysis are depicted (A). Climbing 
speed was measured at 14th day time-point. Six treatment combinations for gene 
expression comparison are shown (B). Expression profiles were generated at 10th 
and 14th day time-points. NF , normal food; ETH, ethosuximide; GBP , gabapentin; 
VGB, vigabatrin; NaVP , sodium valproate, LEV, levetiracetam. See text for details.www.frontiersin.org  March 2011  | Volume 5  | Article 161  |  3
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mixture was denatured at 65°C and applied onto microarray slides. 
The slides were covered by a 24 mm × 60 mm coverslip (ESCO, 
Portsmouth, USA). Hybridization was carried out in a hybridiza-
tion chamber (Corning) at 37°C for 16 h. After hybridization, slides 
were submerged in a solution containing 1× SSC and 0.1% SDS 
at 50°C, to remove the coverslips. Slides were washed in 1× SSC 
and 0.1% SDS at 50°C (three times for 15 min each) and then in 
1× SSC at room temperature (twice for 15 min each). Slides were 
further washed in 0.1× SSC for 15 min and the liquid remaining 
on the slides after washing was quickly removed by spinning the 
slides at 600 rpm for 5 min.
Slides were scanned at 10 μm resolution using GenePix 4000A 
Microarray Scanner (Molecular Devices) and the images preproc-
essed and quantified using Gene Pix Pro 6.0 (Molecular Devices). 
Ratio based data normalization and selection of features were 
performed using Acuity 4.0 (Molecular Devices). All Spots with 
raw intensity less then 100 U and less then twice the average back-
ground was ignored during normalization. Normalized data was 
filtered for the selection of features before further analysis. Only 
those spot were selected which contained a small percentage (<3) 
of saturated pixels, were not flagged bad or found absent (flags > 0), 
had relatively uniform intensity and uniform background [Rgn R2 
(635/532) > 0.6] and were detectable above background (SNR > 3). 
Analyzable spots in at least three of four biological replicates per-
formed were retrieved for downstream analysis using significant 
analysis of microarrays (SAM 3.0, Excel Add-In), under the con-
ditions of one class response and 100 permutations (Tusher et al., 
2001). Normalized log2 ratio (635/532) of four biological replicates 
with balanced dye-swaps was used for microarray clustering using 
Acuity 4.0 (Molecular Devices). Details of RNA extraction and 
microarray analysis have been described previously (Mohammad 
et al., 2009). The full microarray data set has been deposited in 
the Gene Expression Omnibus1 under accession series GSE7156, 
GSE10984, GSE10985, GSE10986, GSE10987, and GSE10988.
the dots and commas were accordingly transformed in the activity 
and rest period. Climbing speed was calculated using the following 
formula, s = h/t, where s = climbing speed, h = height climbed in 
centimeter, and t = activity period in second.
MIcroarray analysIs
Total cellular RNA was isolated from fly heads belonging to four 
biological replicates. Microarray – cDNA Synthesis Kit, – Target 
Purification Kit, and – RNA Target Synthesis Kit (Roche) were 
used to generate labeled antisense RNA. Starting with 10 μg of 
total  cellular  RNA,  Eberwine  method  (kits  from  Roche)  was 
used to generate cDNA and thereafter Cy3 and Cy5 (Amersham) 
labeled antisense RNA. The Cy3 and Cy5 labeled aRNAs (control 
and treated) were pooled together and precipitated, washed, air-
dried, and dissolved in 18 MΩ RNAase free water. A total of 48 
microarrays were hybridized, four each for 10th and 14th day flies 
not treated with any AED and 10th and 14th day flies treated with 
each of the five AEDs separately (Figure 1B). The arrays used in 
the experiment (Canadian Drosophila Microarray Centre, Toronto) 
represent over 10000 unique D. melanogaster genes and are available 
for distribution to academic labs. Each microarray compared RNA 
abundance in drug exposed flies versus flies never exposed to any 
drug at any time, i.e., maintained throughout in NF. Out of four 
slides representing four biological replicates, two were dye-swaps. 
Each biological replicate represented RNA isolated from heads of 
120 control or treated flies. These flies were collected from four vials, 
with 30 flies housed in each. The control and drug fed flies were 
always treated in parallel. The four biological replicates represented 
control and treated flies collected on four different days. Microarray 
hybridization was set-up on eight different days, four each for 10th 
and 14th day time-points. A single biological replicate of each of the 
six comparisons to be carried out for a given time-point were proc-
essed together and used for hybridization in parallel, on a single day 
(Figure 2). Hybridization solution contained hybridization buffer 
(DIG Easy Hyb, Roche), 10 mg/ml salmon testis DNA (0.05 mg/ml 
final concentration, Sigma), 10 mg/ml yeast tRNA (0.05 mg/ml final 
concentration, Sigma), and the Cy3 and Cy5 labeled product. The 
Figure 2 | Batch structure of microarrays. Microarrays were run in eight batches. Each batch comprised of one of the four biological replicates belonging to 12 
comparisons depicted in Figure 1. Fly treatment, RNA isolation, labeling, hybridization, and scanning were carried out separately for each of the eight batches.
1http://www.ncbi.nlm.nih.gov/geo/Frontiers in Neuroscience  | Neurogenomics    March 2011  | Volume 5  | Article 161  |  4
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reliable. In the present analysis, we used Student’s t-test with nominal 
p-value for pair-wise comparisons. As expected from the previous 
report (Mohammad et al., 2009), PTZ withdrawal alone caused an 
increased climbing speed compared to NF (Figure 3). However, 
climbing speed of flies treated with either of the AEDs except ETH 
did not differ significantly from that of NF control. In ETH group 
also, though the flies showed higher speed than NF (p = 0.013), the 
difference was far less significant compared to that observed between 
PTZ withdrawal alone and NF (p = 0.00000017). In AED alone 
group, none except VGB caused a significantly altered speed. The 
observed rescuing effect of GBP, NaVP, and LEV in post-PTZ with-
drawal flies was thus found not to be confounded by their locomotor 
effect in normally grown flies. Cumulatively, the AEDs in general 
normalized the behavioral perturbation caused by PTZ withdrawal.
transcrIptoMIc effect of ptZ Is norMalIZed By aeds
Differentially expressed genes
We next asked the question if AEDs in general normalize the tran-
scriptomic perturbation caused by PTZ withdrawal. To explore this, 
microarray gene expression profiles of fly heads were generated at 
two time-points – 3rd and 7th day after PTZ withdrawal, i.e., on 10th 
and 14th day from the start of PTZ treatment. Twelve sets of flies 
were profiled, six each for 10th and 14th day time-points (Figure 2). 
In one set each for the two time-points, flies were not treated with 
any AED after PTZ withdrawal (Figure 2). In five other sets for each 
time-points, flies were treated with PTZ for 7 days, with one of the 
five AEDs for 3 days (10th day time-point), or with NF for 4 days 
(14th day time-point), in that order (Figure 2). Flies treated in par-
allel with NF throughout were used for comparison, in each of the 
12 sets of microarrays. Four biological replicates comprised each set 
of microarray; one set compared PTZ withdrawal with NF control, 
and the rest compared ETH, GBP, VGB, NaVP, or LEV treatment 
after PTZ withdrawal with NF control (Figure 2). In a preliminary 
analysis, we observed an increasing enrichment of GO biological 
processes in differentially expressed genes up to 15% false discovery 
rate (FDR). Previously, a control microarray experiment that used 
the same method which was followed here compared NF versus NF 
flies and reported no differentially expressed gene below 96% FDR 
(Mohammad et al., 2009). Considering the above, we used 15% FDR 
cut-off for identifying differentially expressed genes. Genes were 
found to be differentially expressed in all the six sets of microarrays, 
in both 10th and 14th day time-points. The up- and down-regulated 
BIoInforMatIcs
FLIGHT2 was used for retrieving gene symbols and IDs. The GOTool 
Box (Martin et al., 2004) was used to retrieve overrepresented gene 
ontology (GO) biological processes in up- or down-regulated genes. 
The GOTool Box was used under the settings, ontology,   biological 
process; mode, all terms; reference, genome; evidence, all–all evidence; 
species, D. melanogaster; GO-stats3. DAVID4 was used for examining 
enrichment of pathways in Kyoto encyclopedia of genes and genomes 
(KEGG) database using modified Fisher exact test (Dennis et al., 2003; 
Huang et al., 2009). Genes showing pathway enrichment in DAVID 
analysis were depicted in the KEGG maps for D. melanogaster5.
results
BehavIoral effect of ptZ Is norMalIZed By aeds
We first examined the behavioral pharmacology of AEDs in the fly 
model. In this analysis, flies were treated with PTZ for 7 days, with an 
AED for 3 days, and with NF for 4 days, in that order, before climb-
ing speed was measured (Figure 1A). In parallel, flies were treated 
either with NF for the entire 14 days, or with PTZ for first 7 days and 
then by NF for rest of the period, or with NF, AED, and NF for 7, 3, 
and 4 days in sequence (Figure 1A). Previously, a control climbing 
assay using the same method followed here detected no significant 
variation among various batches of NF flies housed in different vials, 
neither in one-way ANOVA nor in two-tailed, pair-wise Student’s 
t-test with p-value unadjusted for multiple testing (Mohammad 
et al., 2009). This demonstrated that climbing speed measurement 
was a robust assay and pair-wise comparison at nominal p-value is 
Figure 3 | Behavioral pharmacology of AeDs. Mean ± SE (n = 24) of 
climbing speed of flies treated and untreated with AED after PTZ withdrawal, 
and treated with AED alone. Note that climbing speed of flies treated with an 
AED after PTZ withdrawal is either insignificantly or less significantly different 
from the control (NF) group, compared to flies not treated with an AED after 
PTZ withdrawal. PTZ indicates no AED treatment after PTZ withdrawal, AED 
abbreviation indicates AED alone treatment, PTZ + AED abbreviation indicates 
AED treatment after PTZ withdrawal. Speed in the control (NF) group was 
compared with various treatment groups, in pair-wise comparisons. *Indicates 
nominal p-value. See text for details.
Table 1 | Numbers of SAM analyzable spot iDs and differentially 
expressed genes in microarray profiles of flies treated with or without 
AeDs after PTZ withdrawal.
  No AeD  eTH  gBP  VgB  NaVP  LeV
10TH DAy
Analyzable spots  7877  9450  8593  7443  8775  2760
Upregulated genes  929  1  0  0  0  4
Downregulated genes  49  0  8  283  1  4
14TH DAy
Analyzable spots  6353  5107  4473  5609  5505  2651
Upregulated genes  48  0  0  42  0  0
Downregulated genes  158  7  203  648  104  5
2http://www.flight.licr.org/search/batch_homology.jsp
3http://burgundy.cmmt.ubc.ca/GOToolBox/
4http://david.abcc.ncifcrf.gov/home.jsp
5http://www.genome.jp/kegg/tool/color_pathway.htmlwww.frontiersin.org  March 2011  | Volume 5  | Article 161  |  5
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Table 2 | enriched gO processes in differentially expressed genes in flies treated with or without AeDs after PTZ withdrawal.
gO_iD  Term  p-value*
10TH DAy, uPreguLATeD, PTZ wiTHDrAwAL, NO AeD
GO:0008152  Metabolic process  3.53E-09
GO:0044238  Primary metabolic process  3.96E-09
GO:0006139  Nucleobase, nucleoside, nucleotide,   2.48E-07 
  and nucleic acid metabolic process 
GO:0043283  Biopolymer metabolic process  6.22E-07
GO:0044237  Cellular metabolic process  1.28E-06
GO:0043170  Macromolecule metabolic process  1.58E-06
GO:0009987  Cellular process  1.06E-05
GO:0034960  Cellular biopolymer metabolic process  2.23E-05
GO:0009058  Biosynthetic process  5.58E-05
GO:0044249  Cellular biosynthetic process  6.06E-05
GO:0044260  Cellular macromolecule metabolic process  7 .72E-05
GO:0034961  Cellular biopolymer biosynthetic process  0.0001
GO:0043284  Biopolymer biosynthetic process  0.0001
gO:0006350  Transcription  0.00016
gO:0010467  gene expression  0.00017
GO:0065007  Biological regulation  0.0002
GO:0050794  Regulation of cellular process  0.0004
gO:0006366  Transcription from rNA  0.0004 
  polymerase ii promoter
GO:0034645  Cellular macromolecule  0.0006 
  biosynthetic process
GO:0009059  Macromolecule biosynthetic process  0.0006
gO:0016070  rNA metabolic process  0.0008
GO:0050789  Regulation of biological process  0.001
GO:0010556  Regulation of macromolecule  0.003 
  biosynthetic process 
gO:0006357  regulation of transcription from  0.004 
  rNA polymerase ii promoter 
GO:0065003  Macromolecular complex assembly  0.004
GO:0031326  Regulation of cellular biosynthetic process  0.004
GO:0009889  Regulation of biosynthetic process  0.004
GO:0043933  Macromolecular complex  0.005 
  subunit organization 
gO:0045449  regulation of transcription  0.007
gO:0006351  Transcription, DNA-dependent  0.007
gO:0032774  rNA biosynthetic process  0.008
GO:0019219  Regulation of nucleobase, nucleoside,   0.009 
  nucleotide, and nucleic acid metabolic process
gO:0010468  regulation of gene expression  0.012
GO:0034621  Cellular macromolecular  0.017 
  complex subunit organization
GO:0080090  Regulation of primary metabolic process  0.021
gO:0007154  Cell communication  0.031
GO:0034622  Cellular macromolecular complex assembly  0.036
GO:0060255  Regulation of macromolecule  0.036 
  metabolic process
10TH DAy, DOwNreguLATeD, PTZ wiTHDrAwAL, NO AeD
GO:0044237  Cellular metabolic process  0.024
10TH DAy, DOwNreguLATeD, PTZ wiTHDrAwAL, gBP
GO:0006629  Lipid metabolic process  0.016
GO:0009636  Response to toxin  0.05
gO_iD  Term  p-value*
10TH DAy, DOwNreguLATeD, PTZ wiTHDrAwAL, LeV
GO:0048252  Lauric acid metabolic process  0.002
GO:0031000  Response to caffeine  0.007
GO:0014074  Response to purine  0.007
GO:0009404  Toxin metabolic process  0.02
GO:0017143  Insecticide metabolic process  0.02
GO:0006805  Xenobiotic metabolic process  0.02
GO:0009410  Response to xenobiotic stimulus  0.02
GO:0014070  Response to organic cyclic substance  0.04
GO:0043279  Response to alkaloid  0.04
GO:0017085  Response to insecticide  0.046
14TH DAy, DOwNreguLATeD, PTZ wiTHDrAwAL, eTH
GO:0009636  Response to toxin  0.0051
14TH DAy, DOwNreguLATeD, PTZ wiTHDrAwAL, gBP
GO:0008152  Metabolic process  3.36E-06
GO:0016052  Carbohydrate catabolic process  0.00012
GO:0046164  Alcohol catabolic process  0.0024
GO:0050896  Response to stimulus  0.0053
GO:0006091  Generation of precursor  0.006 
  metabolites and energy 
GO:0044237  Cellular metabolic process  0.006
GO:0009636  Response to toxin  0.02
GO:0044275  Cellular carbohydrate catabolic process  0.03
GO:0044248  Cellular catabolic process  0.03
14TH DAy, uPreguLATeD, PTZ wiTHDrAwAL, VgB
GO:0014866  Skeletal myofibril assembly  0.047
14TH DAy, DOwNreguLATeD, PTZ wiTHDrAwAL, VgB
GO:0008152  Metabolic process  6.04E-11
GO:0000022  Mitotic spindle elongation  5.01E-07
GO:0051231  Spindle elongation  6.31E-07
GO:0044237  Cellular metabolic process  1.37E-06
GO:0044238  Primary metabolic process  3.30E-05
GO:0019538  Protein metabolic process  6.66E-05
GO:0044267  Cellular protein metabolic process  9.63E-05
GO:0044248  Cellular catabolic process  0.0006
GO:0006412  translation  0.0007
GO:0007052  Mitotic spindle organization  0.001
GO:0050896  Response to stimulus  0.002
GO:0006950  Response to stress  0.005
GO:0009056  Catabolic process  0.009
GO:0007051  Spindle organization  0.03
14TH DAy, DOwNreguLATeD, PTZ wiTHDrAwAL, NAVP
GO:0009636  Response to toxin  2.86E-06
GO:0050896  Response to stimulus  0.0003
GO:0009056  Catabolic process  0.0003
GO:0016052  Carbohydrate catabolic process  0.004
GO:0005975  Carbohydrate metabolic process  0.008
GO:0008152  Metabolic process  0.03
14TH DAy, DOwNreguLATeD, PTZ wiTHDrAwAL, LeV
GO:0015782  CMP-sialic acid transport  0.03
GO:0015789  UDP-N-acetylgalactosamine transport  0.03
GO:0015757  Galactose transport  0.03
Gene expression and cell communication related processes are highlighted in bold.
*After Bonferroni correction.Frontiers in Neuroscience  | Neurogenomics    March 2011  | Volume 5  | Article 161  |  6
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genes are listed in Table S1 in Supplementary Material. The numbers 
of differentially expressed genes and the total analyzable spots in 
significant analysis of microarrays (SAM) are provided in Table 1. 
Differentially expressed genes in AED untreated flies (Table S1 in 
Supplementary Material) showed significant overlap between 10th 
and 14th day, in a direction-specific manner: 20 genes were common 
between 929 upregulated genes on 10th day and 48 upregulated genes 
on 14th day; 10 genes were common between 49 downregulated genes 
on 10th day and 158 downregulated genes on 14th day. Considering 
the total number of unique genes represented in the arrays as 10500, 
these overlaps were extremely significant (hypergeometric distribu-
tion p = 9E-10 and 2E-09, in that order). These results were not 
surprising because a significant overlap is expected at adjacent time-
points. Very small number of differentially expressed genes (or no 
such genes) precluded similar analysis for AED treated profiles. 
Overall, the above analysis proved the robustness of the array data.
Table 3 | enriched processes in gene expression and cell communication 
related upregulated genes in AeD untreated flies.
Term  p-value*
geNe exPreSSiON
dme03040:spliceosome  0.001
dme03018:RNA degradation  0.006
dme03010:ribosome  0.049
CeLL COMMuNiCATiON
dme00562:inositol phosphate metabolism  0.012
dme04070:phosphatidylinositol signaling system  0.02
dme04144:endocytosis  0.027
dme04340:hedgehog signaling pathway  0.046
*Nominal.
Figure 4 | genes mapping to Kegg pathway for spliceosome. Pink boxes 
represent upregulated genes in AED untreated flies. These genes are Hsp68 
(Heat shock protein 68), U2af50 (U2 small nuclear riboprotein auxiliary factor 50), 
snRNP69D (small nuclear ribonucleoprotein at 69D), and snRNP70K (small 
nuclear ribonucleoprotein 70K). Green boxes represent other members in the 
pathway database for Drosophila melanogaster.www.frontiersin.org  March 2011  | Volume 5  | Article 161  |  7
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to flies without AED treatment, the GBP and VGB treated flies 
displayed higher number of differentially expressed genes on 14th 
day. Together, AED treatment in general was found to reduce the 
number of differentially expressed genes on 10th day, i.e., the time-
point till which flies were treated with the AEDs.
Process enrichment analysis
We next examined enrichment of GO biological processes in the 
differentially expressed genes. In AED untreated flies, the genes 
upregulated on 10th day showed enrichment for GO processes 
Using 2 × 2 chi-square test with Yates’ correction for continuity, 
we compared the number of analyzable spots and the number of 
up- and down-regulated genes in flies without AED treatment with 
corresponding numbers in AED treated flies. A pair-wise compari-
son revealed extremely significant difference in these numbers, 
for 10th as well as 14th day time-points. The p-values obtained 
for all the 10 comparisons, five each for 10th and 14th day time-
points, were in the range of 0.00–0.0009. All comparisons except 
that with 14th day GBP and 14th day VGB showed reduction in 
the number of differentially expressed genes by AEDs. Compared 
Figure 5 | genes mapping to Kegg pathway for rNA degradation. Pink 
boxes represent upregulated genes in AED untreated flies. These genes are 
Csl4 (CG6249 gene product from transcript CG6249-RA), Dis3 (CG6413 gene 
product from transcript CG6413-RA), and Rrp6 (CG7292 gene product from 
transcript CG7292-RB). Green boxes represent other members in the pathway 
database for Drosophila melanogaster.Frontiers in Neuroscience  | Neurogenomics    March 2011  | Volume 5  | Article 161  |  8
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observation (Table 1) that AEDs in general normalize the transcrip-
tomic perturbation, the GO enrichment analysis further suggested 
that AEDs cause normalization of perturbation in several processes 
including gene expression and cell communication.
Pathway enrichment analysis
To gain further insights into the normalizing effect of AEDs on 
PTZ withdrawal induced transcriptomic perturbation, we next 
examined if gene expression (GO:0010467) and cell communica-
tion (GO:0007154) related upregulated genes in AED untreated 
flies on 10th day enrich specific pathways. Notably, several path-
ways were found to be overrepresented in the two sets of genes 
(Table 3) – the gene set belonging to gene expression category 
showed enrichment for spliceosome, RNA degradation and ribos-
ome, and the gene set belonging to cell communication enriched 
inositol phosphate metabolism, phosphatidylinositol signaling, 
endocytosis, and hedgehog signaling. The upregulated genes are 
mapped on to KEGG pathways for visualization (Figures 4–10).
related to metabolism, gene expression and cell communication, 
and the downregulated genes that for cellular metabolic process 
(Table 2). Neither upregulated nor downregulated gene set repre-
senting 14th day time-point showed enrichment for any process. In 
AED treated flies, differentially expressed genes in 10th day showed 
enrichment of processes only in the flies treated with GBP and LEV, 
not ETH, VGB, and NaVP (Table 2). These enriched processes were 
related to metabolism. In 14th day time-point, genes differentially 
regulated by AEDs were found to enrich various processes. These 
processes were related to metabolism, response to toxin, skeletal 
myofibril  assembly,  spindle  elongation,  translation,  CMP-sialic 
acid transport, etc. (Table 2). Notably, gene expression and several 
related processes such as transcription, transcription from RNA 
polymerase II   promoter, RNA metabolic process, RNA biosynthetic 
process etc. were enriched in genes upregulated in flies that were 
not treated with any AED (Table 2). Also notable was the enrich-
ment of cell communication, besides others, in genes upregulated 
in AED untreated group (Table 2). Combined with the previous 
Figure 6 | genes mapping to Kegg pathway for ribosome. Pink boxes 
represent upregulated genes in AED untreated flies. These genes are RpL15 
(Ribosomal protein L15), RpL28 (Ribosomal protein L28), RpL38 (Ribosomal 
protein L38), RpL39 (Ribosomal protein L39), and RpL5 (Ribosomal protein L5). 
Green boxes represent other members in the pathway database for Drosophila 
melanogaster.  www.frontiersin.org  March 2011  | Volume 5  | Article 161  |  9
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Microarray clustering
Transcriptomic  analysis  so  far  depended  exclusively  on  differ-
entially expressed genes selected using a FDR cut-off. To further 
examine if AEDs indeed remodel PTZ withdrawal induced tran-
scriptomic perturbation, we next clustered the microarray profiles 
of flies with or without AED treatment. The hierarchical cluster-
ing that uses expression values of all the analyzable spots in the 
microarrays clearly separated the time series profiles of AED treated 
and untreated flies (Figure 11). Microarray clustering thus overall 
confirmed the transcriptome remodeling effect of AEDs.
dIscussIon
We have shown here that AEDs normalize long term behavioral 
and transcriptomic alterations induced by PTZ withdrawal in 
a Drosophila model. Our evidence further suggests that AEDs’ 
transcriptomic effect is mediated by neutralization of upregu-
lated genes related to various processes including gene expres-
sion and cell communication. Furthermore, our results suggest 
that AEDs neutralize upregulation of genes belonging to several 
pathways. In the cell communication category, these pathways 
are inositol phosphate metabolism, phosphatidylinositol signal-
ing, endocytosis, and hedgehog signaling. In the gene expression 
category, these pathways are spliceosome, RNA degradation, and 
ribosome. It is important to note here that cell communication 
pathways  have  previously  been  implicated  in  the  therapeutic 
mechanisms of AEDs and antipsychotic drugs in diverse stud-
ies. For example, biochemical and neurobiological evidence has 
earlier suggested that NaVP and LEV inhibit inositol metabo-
lism and/or phosphatidylinositol signaling (Simister et al., 2007; 
Xu et al., 2007; Nagarkatti et al., 2008; Tokuoka et al., 2008; Teo 
et al., 2009; Yamamura et al., 2009). Also, cell biological evidence 
has shown NaVP induced reduction in endocytosis, a process 
that is linked to phosphatidylinositol signaling (Xu et al., 2007). 
Similarly, transcriptomic evidence showing increased expression 
of endocytosis related genes in phenytoin resistant kindled rats, 
a model of epileptogenesis, has previously been presented (Zeng 
et al., 2009). Further, several antipsychotic drugs have recently 
been found to regulate hedgehog signaling (Lauth et al., 2010), 
a pathway that, besides its established role in adult CNS, is also 
known for its growth enhancing effect in the adult brain (Tsuboi 
and Shults, 2002; Dellovade et al., 2006).
Regarding gene expression related pathways, though transcrip-
tion factors and mRNA expression have earlier been implicated 
(Atmaca, 2009; Heinrich et al., 2009; Christensen et al., 2010; 
Figure 7 | genes mapping to Kegg pathway for inositol phosphate 
metabolism. Pink boxes represent upregulated genes in AED untreated flies. 
These genes are IP3K2 (Inositol 1,4,5-triphosphate kinase 2), Ipk1 (CG30295 gene 
product from transcript CG30295-RB), Ipp (Inositol polyphosphate 1-phosphatase), 
and PIP5K59B (CG3682 gene product from transcript CG3682-RA). Green boxes 
represent other members in the pathway database for Drosophila melanogaster.Frontiers in Neuroscience  | Neurogenomics    March 2011  | Volume 5  | Article 161  |  10
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a subset of the total genes represented on the microarrays, due to 
the loss of a large number of genes during downstream processing 
of the data. More sensitive labeling, hybridization, and detection 
system, such as those provided by Affymetrix platform, could have 
possibly minimized this loss and resulted in the identification of 
additional differentially expressed genes and, in turn, enrichment 
of additional processes and pathways.
Acute biochemical effects of drugs used in treating neuropsy-
chiatric disorders do not provide simple mechanistic interpre-
tations for the observed neuroprotection (Zhou et al., 2009). 
Instead, genomic effects of these drugs are considered to ulti-
mately translate into the overall neuroprotection (Altar et al., 
2009). Given this, it is significant that transcriptomic analysis in 
a novel Drosophila model has provided evidence that is consist-
ent with known effect of drugs reported in mammalian studies. 
Amenable to various experimental approaches, the Drosophila 
model may thus offer a unique opportunity to further under-
stand the psychotropic drug mechanism in cellular and molecular 
Girgenti et al., 2010), the involvement of spliceosome, RNA deg-
radation, and ribosomal pathways has not been well documented 
in the therapeutic mechanism of AEDs. It is therefore notable that 
our study has identified these three pathways as additional candi-
dates in the therapeutic mechanism. Altered regulation of RNA 
metabolism including splicing, mRNA stability, etc., are known 
to be associated with various neurological and psychiatric disor-
ders (Licatalosi and Darnell, 2006; Anthony and Gallo, 2010). Also, 
recent biochemical studies have shown that phosphatidylinositol 
signaling is linked to mRNA processing and translation (Kiefer 
et al., 2009; Laserna et al., 2009; Lewis et al., 2011). The above 
evidence supports our results that implicate a spectrum of gene 
expression and cell communication pathways in the therapeutic 
mechanism of neuropsychiatric disorders. It is intriguing though 
that we did not find enrichment of processes related to synaptic 
function in differentially expressed genes, as would be expected for 
proconvulsant and anticonvulsant drugs. It may however be noted 
here that our transcriptomic results are based on the analysis of only 
Figure 8 | genes mapping to Kegg pathway for phosphatidylinositol 
signaling system. Pink boxes represent upregulated genes in AED untreated flies. 
These genes are IP3K2 (Inositol 1,4,5-triphosphate kinase 2), Ipk1 (CG30295 gene 
product from transcript CG30295-RB), Ipp (Inositol polyphosphate 1-phosphatase), 
and PIP5K59B (CG3682 gene product from transcript CG3682-RA). Green boxes 
represent other members in the pathway database for Drosophila melanogaster.www.frontiersin.org  March 2011  | Volume 5  | Article 161  |  11
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Figure 9 | genes mapping to Kegg pathway for endocytosis. Pink boxes 
represent upregulated genes in AED untreated flies. These genes are Gap69C 
(GTPase-activating protein 69C), Hsp68 (Heat shock protein 68), PIP5K59B 
(CG3682 gene product from transcript CG3682-RA), TSG101 (tumor suppressor 
protein 101), Vps20 (Vacuolar protein sorting 20), alpha-Adaptin (CG4260 gene 
product from transcript CG4260-RA), cenG1A (centaurin gamma 1A), and schizo 
(K12495 IQ motif and SEC7 domain-containing protein). Green boxes represent 
other members in the pathway database for Drosophila melanogaster.
Figure 10 | genes mapping to Kegg pathway for hedgehog signaling. Pink boxes represent upregulated genes in AED untreated flies. These genes are Rab23 
(CG2108 gene product from transcript CG2108-RA), dpp (decapentaplegic), and fu (fused). Green boxes represent other members in the pathway database for 
Drosophila melanogaster.Frontiers in Neuroscience  | Neurogenomics    March 2011  | Volume 5  | Article 161  |  12
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terms. Methods in fly genetics, for example, may be used to func-
tionally validate candidate genes in the pathways. Similarly, epige-
netic approaches could be applied to understand long term drug 
effects in brain plasticity. Besides, the fly model may directly be 
used for drug screening using behavioral and functional genomic 
readouts. It is tempting to note here that we are currently imple-
menting the fly model in screening drugs approved by Food 
and Drug Administration (USA) toward potential repurposing. 
The preliminary results obtained so far are indeed encouraging. 
Further screening of positive compounds in a battery of rodent 
models available for epileptogenesis, and neuropsychiatric and 
neurodegenerative disorders will be crucial. In brief, the fly model 
promises to accelerate the pace of discovery in the area of CNS 
disorders and therapy.
Figure 11 | Hierarchical clustering of microarrays. Microarrays of 10th 
and 14th day time-points are clustered to examine separation of profiles 
of flies untreated with an AED and flies treated with the AEDs ETH 
(A), NaVP (B), LEV (C), VGB (D), and GBP (e) after PTZ withdrawal. 
Note clear separation of the two groups. The AED untreated group is 
indicated by PTZ, and the AED treated groups by AED abbreviation. 
Jaccard similarity metric and average linkage methods were used 
for clustering.www.frontiersin.org  March 2011  | Volume 5  | Article 161  |  13
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